GoodRx Holdings, Inc. - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. GoodRx Holdings, Inc. operates a digital healthcare platform providing prescription price comparison, savings codes, subscription services (GoodRx Gold, condition-specific plans), and Pharma Direct solutions. The company is an accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $200.4 million | $203.1 million | $394.4 million | $406.0 million |
| Net Income | $8.5 million | $12.8 million | $9.7 million | $23.9 million |
| Net Income Margin | 4.3% | 6.3% | 2.5% | 5.9% |
| Adjusted EBITDA | $63.7 million | $69.4 million | $122.0 million | $139.2 million |
| Adjusted EBITDA Margin | 31.8% | 34.2% | 30.9% | 34.3% |
| Cash & Equivalents | $296.1 million | N/A | N/A | N/A |
| Operating Cash Flow (YTD) | $92.7 million | $59.0 million | N/A | N/A |
| Debt (Term Loan Principal) | $492.5 million | N/A | N/A | N/A |
Note: Debt includes a $500M term loan maturing in 2029 and an $88M revolving credit facility with $80.4M available.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 1.3% YoY in Q2 and 2.9% YoY YTD. This was driven primarily by a 26% drop in Prescription Transactions revenue ($106.4M vs $143.1M) due to reduced Monthly Active Consumers (5.0M vs 5.7M) and lower unit economics.
- Segment Growth: Despite the overall decline, Pharma Direct revenue surged 76% YoY ($61.6M vs $34.9M) and Subscription revenue grew 39% YoY ($28.5M vs $20.5M), reflecting a strategic shift toward these offerings.
- Profitability Pressure: Net income margin contracted to 4.3% in Q2 from 6.3% in the prior year, largely due to higher cost of revenue (up 57% YoY) associated with scaling subscription and delivery services.
- Balance Sheet Shift: Prescription reimbursement assets and liabilities increased significantly (to $1.08B and $1.04B respectively) due to changes in presentation and volume in consumer direct pricing programs.
Outlook, Risks, and Management Commentary
- Strategic Pivot: Management is deliberately shifting investment from the foundational prescription transactions offering toward Pharma Direct and subscription services. They expect near-term pressure on Monthly Active Consumers and unit economics to persist in 2026 as they prioritize long-term durability.
- External Headwinds: The company cites adverse impacts from the U.S. retail pharmacy landscape, including store closures (Rite Aid, Walgreens) and volume reductions in integrated savings programs. The bankruptcy of Rite Aid caused immediate claim cessation.
- Government Initiatives: GoodRx is an integration partner for the new government-sponsored "TrumpRx.gov" platform. While initial utilization appears incremental, the long-term impact remains uncertain and could be material.
- Legal Contingencies: A consumer privacy class action settlement of $25.0 million is pending court approval. An additional $5.5 million is accrued for indemnification. The company has not accrued for other pending state litigations (Arkansas, Minnesota) as losses are not deemed probable.
- Liquidity: The company maintains $296.1 million in cash and $80.4 million in available revolver capacity, deemed sufficient for the next 12 months.
Investor Verification Checklist
- Sustainability of Revenue Mix: Verify if the growth in Pharma Direct and Subscriptions can fully offset the structural decline in Prescription Transactions revenue.
- Legal Settlement Finality: Monitor the court approval status of the $25M privacy class action settlement and potential for additional litigation costs.
- TrumpRx Impact: Assess whether the government platform acts as a net positive (incremental demand) or a competitor displacing GoodRx traffic.
- Unit Economics: Review future quarters for stabilization of cost of revenue as the new subscription and delivery models scale.
- Debt Covenants: Confirm continued compliance with the First Lien Net Leverage Ratio covenant, especially given the shift in revenue composition.